Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-802 in advanced solid tumors
NCT05268666Phase 2Unknown
- Sponsor
- Jubilant Therapeutics Inc.
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JBI-802 in solid tumor (advanced stage), small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), neuroendocrine tumors (NETs), sponsored by Jubilant Therapeutics Inc.. Status: unknown.
02
Drugs
JBI-802
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)neuroendocrine prostate cancer (NEPC)neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT05268666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268666.